Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
Clinical trial NCT07554898 · RECRUITING
Trial details
- NCT number
- NCT07554898
- Sponsor
- Zhejiang Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-16
- Primary completion
- 2028-02-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.